Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed
Authors:
- G.J PetersG.J Peters
- B van TriestBTB van Triest
- H.H.J BackusHBH.H.J Backus
- C.M KuiperCKC.M Kuiper
- C.L van der WiltCWC.L van der Wilt
- H.M PinedoHPH.M Pinedo
- 1 May 2000
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 36 (7) , 916-924
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.Journal of Clinical Oncology, 1998
- The proto-oncogene Bcl-2 and its role in regulating apoptosisNature Medicine, 1997
- Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: Evidence for the involvement of RNA perturbationProceedings of the National Academy of Sciences, 1997
- ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group.Journal of Clinical Oncology, 1996
- ‘Tomudex’ (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopeniaEuropean Journal of Cancer, 1995
- P53, cell cycle control and apoptosis: Implications for cancerCancer and Metastasis Reviews, 1995
- Regulators of cell deathTrends in Genetics, 1995
- p53-dependent apoptosis modulates the cytotoxicity of anticancer agentsCell, 1993
- p53, guardian of the genomeNature, 1992
- Clinical relevance of biochemical modulation of 5-fluorouracilAnnals of Oncology, 1991